title: Hyperfractionated radiotherapy for T2 glottic cancer for preservation of the larynx.
abstract: To evaluate the effectiveness of hyperfractionation for T2 glottic cancer from a viewpoint of laryngeal preservation, we analyzed 21 patients (twice-a-day group) who were treated with hyperfractionation between 1992 and 1998 and compared the results with those of 27 patients (once-a-day group) treated with conventional once-a-day radiation between 1987 and 1992. In the twice-a-day group, radiation was performed with two fractions of 1.2 Gy/day up to a total dose of 72-74.4 Gy. In the once-a-day group, radiation was performed with a fraction of 2 Gy/day up to a total dose of 66 Gy. If radiation was ineffective at 40 Gy, it was stopped, and surgical treatment was carried out. Kaplan-Meier estimates were used for the analysis of the survival rate and laryngeal preservation rate, and the results were compared. In the once-a-day group, the 5-year survival rate was 92.3%. The 5-year laryngeal preservation rate was 51.8%, and it was 60.3% in 20 patients who had undergone full-dose radiation (once-a-day full-dose group). In the twice-a-day group, no major complication, such as laryngeal necrosis, was seen in any case, and the 5-year survival rate was 95.3%. The 5-year laryngeal preservation rate was 95.3%, and it was significantly better than that of both the once-a-day group and the once-a-day full-dose group. Hyperfractionation is considered to be useful for preserving the larynx for the treatment of T2 glottic cancer.
authors: Department of Otolaryngology and Head and Neck Surgery, Kyoto University Hospital, Kyoto, Japan.
authors: Ichiro
authors: I
authors: Tateya
authors: Shigeru
authors: S
authors: Hirano
authors: Hisayoshi
authors: H
authors: Kojima
authors: Koichi
authors: K
authors: Omori
authors: Kazuhiko
authors: K
authors: Shoji
authors: Michihide
authors: M
authors: Mitsumori
authors: Yasushi
authors: Y
authors: Nagata
authors: Juichi
authors: J
authors: Ito
mesh_terms: D000368:Aged; D019583:Dose Fractionation, Radiation; D004307:Dose-Response Relationship, Radiation; D005260:Female; D005500:Follow-Up Studies; D005931:Glottis; D006801:Humans; D007822:Laryngeal Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000532:radiotherapy*; D007828:Laryngoscopy / Q000379:methods; D007830:Larynx / Q000528:radiation effects*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012189:Retrospective Studies; D049489:Stroboscopy; D015996:Survival Rate / Q000639:trends; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome